Nogapendekin alfa inbakicept

因奇西普/诺格白介素α

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NameNogapendekin alfa inbakicept
Drug Alias NameIL-15N72D:IL-15RαSu/Fc fusion protein complexinbakicept in complex 1:2 with nogapendekin alfanogapendekin alfa inbakicept-pmlnIL-15N72D/IL-15Ra-FcIL-15sa +[12] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionImmunostimulantsInterleukin-15 receptors agonists
TargetsInterleukin-15 receptors
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaImmunoparalysis +[64] 
Global Approved IndicationsUrinary Bladder Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/04/22
Country/TerritoryUnited StatesThailandPuerto Rico +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAltor Bioscience Corp
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteImmunitybio IncCigalah Group +[13] 
Inactive CompaniesUtah State UniversityUniversity Of MinnesotaNantcell Inc +[4] 
Active IndicationsSolid tumoursPost-Acute COVID-19 SyndromeMismatch Repair Deficient Cancer +[41] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaImmunoparalysis +[23] 

Other Information

ATC CodeN/A
Related LinksN/A